Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2016

  • ID: 3720466
  • Drug Pipelines
  • 221 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Celgene Corporation
  • Coare Biotechnology, Inc.
  • Forty Seven Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • MORE
Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2016

Summary

‘Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2016’, provides an overview of the Pancreatic Ductal Adenocarcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pancreatic Ductal Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatic Ductal Adenocarcinoma and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma
- The report reviews pipeline therapeutics for Pancreatic Ductal Adenocarcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pancreatic Ductal Adenocarcinoma therapeutics and enlists all their major and minor projects
- The report assesses Pancreatic Ductal Adenocarcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pancreatic Ductal Adenocarcinoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pancreatic Ductal Adenocarcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Celgene Corporation
  • Coare Biotechnology, Inc.
  • Forty Seven Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Pancreatic Ductal Adenocarcinoma Overview

Therapeutics Development

Pipeline Products for Pancreatic Ductal Adenocarcinoma – Overview

Pipeline Products for Pancreatic Ductal Adenocarcinoma – Comparative Analysis

Pancreatic Ductal Adenocarcinoma – Therapeutics under Development by Companies

Pancreatic Ductal Adenocarcinoma – Therapeutics under Investigation by Universities/Institutes

Pancreatic Ductal Adenocarcinoma – Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Pancreatic Ductal Adenocarcinoma – Products under Development by Companies

Pancreatic Ductal Adenocarcinoma – Products under Investigation by Universities/Institutes

Pancreatic Ductal Adenocarcinoma – Companies Involved in Therapeutics Development

AbbVie Inc.

BerGenBio AS

Celgene Corporation

Clovis Oncology, Inc.

Coare Biotechnology, Inc.

Concordia Healthcare Corp.

FibroGen, Inc.

Forty Seven Inc.

Gilead Sciences, Inc.

Halozyme Therapeutics, Inc.

Immodulon Therapeutics Ltd.

Immunomedics, Inc.

Incuron, LLC

Incyte Corporation

Inovio Pharmaceuticals, Inc.

MedImmune, LLC

Medisyn Technologies, Inc.

Merck & Co., Inc.

Nerviano Medical Sciences S.r.l.

OncoMed Pharmaceuticals, Inc.

Oryx GmbH & Co. KG

Sillajen Biotherapeutics

Tara Immuno-Oncology Therapeutics LLC

Tokai Pharmaceuticals, Inc.

Pancreatic Ductal Adenocarcinoma – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

BGB-324 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CBL-0137 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CBT-1111 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CBT-3112 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

demcizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

durvalumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

durvalumab + tremelimumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

epacadostat - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FG-3019 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

galeterone - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Hu-5F9G4 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ibrutinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

idelalisib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IMM-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

INCB-50465 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

INO-1400 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ipafricept - Drug Profile

Product Description

Mechanism of Action

R&D Progress

itacitinib adipate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JX-929 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MK-0752 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MK-8628 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

momelotinib dihydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MRK-003 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MT-477 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NMSP-715 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

paclitaxel albumin bound - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Parvoryx - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PEGPH-20 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

porfimer sodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PSL-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rucaparib phosphate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sacituzumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SBP-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

siG12D-LODER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit Wnt Signal and eIF5A for Pancreatic Cancer - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Modulate GLT-1 for Pancreatic Ductal Adenocarcinoma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

vantictumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Pancreatic Ductal Adenocarcinoma – Recent Pipeline Updates

Pancreatic Ductal Adenocarcinoma - Dormant Projects

Pancreatic Ductal Adenocarcinoma – Discontinued Products

Pancreatic Ductal Adenocarcinoma – Product Development Milestones

Featured News & Press Releases

Jan 27, 2016: FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer

Nov 09, 2015: Compelling Preclinical Data on Sun BioPharma's SBP-101 Presented at the 2015 American Pancreatic Association (APA) Annual Meeting

Oct 20, 2015: Sun BioPharma to Present Three Abstracts at the 2015 American Pancreatic Association Annual Meeting

Jun 25, 2013: Cleveland BioLabs And Incuron Announce Poster Presentation At ESMO 15th World Congress On Gastrointestinal Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H1 2016

Number of Products under Development for Pancreatic Ductal Adenocarcinoma – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by AbbVie Inc., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by BerGenBio AS, H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Celgene Corporation, H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Clovis Oncology, Inc., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Coare Biotechnology, Inc., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Concordia Healthcare Corp., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by FibroGen, Inc., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Forty Seven Inc., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Gilead Sciences, Inc., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Halozyme Therapeutics, Inc., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Immodulon Therapeutics Ltd., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Immunomedics, Inc., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Incuron, LLC, H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Incyte Corporation, H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Inovio Pharmaceuticals, Inc., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by MedImmune, LLC, H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Medisyn Technologies, Inc., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Merck & Co., Inc., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Nerviano Medical Sciences S.r.l., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Oryx GmbH & Co. KG, H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Sillajen Biotherapeutics, H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016

Pancreatic Ductal Adenocarcinoma – Pipeline by Tokai Pharmaceuticals, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pancreatic Ductal Adenocarcinoma Therapeutics – Recent Pipeline Updates, H1 2016

Pancreatic Ductal Adenocarcinoma – Dormant Projects, H1 2016

Pancreatic Ductal Adenocarcinoma – Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H1 2016

Number of Products under Development for Pancreatic Ductal Adenocarcinoma – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AbbVie Inc.
BerGenBio AS
Celgene Corporation
Clovis Oncology, Inc.
Coare Biotechnology, Inc.
Concordia Healthcare Corp.
FibroGen, Inc.
Forty Seven Inc.
Gilead Sciences, Inc.
Halozyme Therapeutics, Inc.
Immodulon Therapeutics Ltd.
Immunomedics, Inc.
Incuron, LLC
Incyte Corporation
Inovio Pharmaceuticals, Inc.
MedImmune, LLC
Medisyn Technologies, Inc.
Merck & Co., Inc.
Nerviano Medical Sciences S.r.l.
OncoMed Pharmaceuticals, Inc.
Oryx GmbH & Co. KG
Sillajen Biotherapeutics
Tara Immuno-Oncology Therapeutics LLC
Tokai Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll